Email this article Biochemical markers of bone metastasis
- Authors: Lyubimova N.V.1, Kushlinskiy N.E.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center
- Issue: Vol 2, No 1 (2015)
- Pages: 061-075
- Section: REVIEW ARTICLES
- Published: 02.06.2015
- URL: https://umo.abvpress.ru/jour/article/view/6
- DOI: https://doi.org/10.17650/2313-805X.2015.2.1.061-075
- ID: 6
Cite item
Full Text
Abstract
Bone metastasis is one of the most frequent and dangerous complications of malignant tumors. The last years, achievements in the study of bone remodeling mechanisms promoted the search of sensitive and specific criteria reflecting the intensity of osteolysis and osteosynthesis in bone metastatic lesions. The most informative and clinically valid biochemical markers of bone formation and resorption are characterized in this review. The data on their possible implications in diagnostics, monitoring and prognosis of skeletal lesions by various malignant tumors are presented. The attention to biochemical markers of bone remodeling as noninvasive methods for oncologic patients examination is gradually increasing with adoption of modern laboratory technologies to clinical practice. The last years, publications suggest the possibility of their use both for monitoring, prognosis and early diagnostics of bone metastasis. We present the results of our own investigation of serum C-telopeptide of type I collagen (СТX) as bone resorption marker and bone-specific alkaline phosphatase (BAP) as formation marker in 238 breast cancer patients using ELISA methods. The elevation of studied biochemical parameters in breast cancer patients was significantly associated with the extent of skeletal metastases (р < 0.02–0.00001), pathological fractures (р < 0.005–0.0001) and the severity of pain (р < 0.01–0.00002). Elevated rate of bone turnover was associated with reduced overall survival of breast cancer patients. The significant difference of overall survival estimated on a base of cut-off values of CTX (0.74 ng/ml) and BAP (43.7 IU/L) was found both in the groups of breast cancer patients with and without bone metastases. Serum СТХ and BAP are of value in monitoring and predicting the status of breast cancer bone metastases.
About the authors
N. V. Lyubimova
N.N. Blokhin Russian Cancer Research Center
Author for correspondence.
Email: biochimia@mtu-net.ru
24 Kashirskoye Highway, Moscow, 115478, Russia Russian Federation
N. E. Kushlinskiy
N.N. Blokhin Russian Cancer Research Center
Email: fake@neicon.ru
24 Kashirskoye Highway, Moscow, 115478, Russia Russian Federation
References
Supplementary files
